Latest Biotech News

Pacific Biosciences unveiled a plan to allow selected customers to reuse its most expensive SMRT cell consumables and launched a new Sprq‑Nx chemistry that raises output and adds...

Two IND clearances this week open clinical development in distinct therapeutic areas. Tr1x Inc. received FDA clearance for TRX‑319 to begin a phase I/IIa study in progressive multiple sclerosis,...

Researchers at Weill Cornell Medicine and the University of Adelaide released GoT‑Multi, a high‑throughput single‑cell multi‑omics method that co‑detects multiple somatic genotypes and whole...

Benchling announced integration of NVIDIA BioNeMo models and NIM microservices into its AI platform, initially enabling users to run OpenFold2 structure predictions inside Benchling and promising...

Tempus AI won a $60 million contract from ARPA‑H to provide testing and contract research services for a project that uses biomarkers to develop adaptive treatment strategies in cancer. The award...

Tubulis completed a large late-stage private financing to accelerate clinical programs for next-generation antibody-drug conjugates (ADCs). The Munich-based biotech secured roughly $360–361...

Kailera Therapeutics closed a $600 million financing led by Bain Capital Private Equity to support global Phase 3 trials of KAI‑9531, a weekly injectable aimed at the same dual targets as Eli...

BioCryst Pharmaceuticals agreed to acquire Astria Therapeutics in a cash-and-stock deal with about $700 million enterprise value to obtain Astria’s long‑acting injectable HAE candidate,...

The FDA pushed back its review decision on Denali Therapeutics’ candidate for Hunter syndrome by three months after the company submitted updated clinical pharmacology information, which the...

Pacific Biosciences announced sequencing chemistry and consumable workflows that let customers wash and reuse SMRT cells on Revio instruments, plus a new Sprq‑Nx chemistry that boosts output and...

Benchling integrated NVIDIA BioNeMo models and NIM microservices into its Benchling AI platform, enabling protein structure prediction (OpenFold2 initially) and laying groundwork for generative...

Weill Cornell Medicine and University of Adelaide researchers released GoT‑Multi, a high‑throughput single‑cell multi‑omics method compatible with FFPE samples that co‑detects multiple somatic...

Novo Nordisk agreed to acquire Akero Therapeutics in a deal that could top $5.2 billion to obtain the FGF21 analogue efruxifermin, which showed fibrosis regression signals in Phase II and...

Researchers engineered Cas9 variants to refine prime editing precision, developing successive editors (pPE, xPE, vPE) that reduce byproduct indels while maintaining efficiency across diverse...

Clinical data and pooled analyses reported that combining radiotherapy with immunotherapy improves outcomes in several difficult cancers. A phase Ib trial showed toripalimab added to concurrent...

Munich-based Tubulis closed a large financing to push its next‑generation antibody‑drug conjugates (ADCs) through clinical development. Reports show the company raised roughly $360–361 million in...

Kailera Therapeutics secured a $600 million Series B to advance its dual‑targeting obesity program into global Phase 3 testing. The Bain Capital‑led round will fund pivotal development of...

Biocryst Pharmaceuticals agreed to acquire Astria Therapeutics for about $700 million in cash and stock, adding Astria’s long‑acting injectable navenibart to Biocryst’s hereditary angioedema (HAE)...

Johnson & Johnson announced plans to spin out its orthopedics unit as a standalone company to be called DePuy Synthes, part of a broader strategy to focus the parent company on higher‑growth...

Pacific Biosciences unveiled new chemistry and a reusable‑consumable workflow aimed at lowering per‑genome costs for high‑accuracy long‑read sequencing, and the company secured selection of its...